Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins

10 Apr 2020

Abstract excerpt

A novel series of macrocyclic pyrazolo[1,5- a ]pyrimidine derivatives as respiratory syncytial virus (RSV) fusion glycoprotein (F protein) inhibitors were designed and synthesized based on docking studies of acyclic inhibitors. This effort resulted in the discovery of several macrocyclic compounds, such as 12b, 12f, and 12h, with low nanomolar to subnanomolar activities against the wild-type RSV F protein A2. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Plant Virus Research Studies
Share to Respiratory viral infections research
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32550994
DOI: 10.1021/acsmedchemlett.0c00008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion ProteinsPMID 32550994Read ↗

Discovery of a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins through the modulation of atropisomer interconversion properties.Semantic proximity Read ↗

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSemantic proximity Read ↗

Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity.Semantic proximity Read ↗

Structure-guided design of small-molecule therapeutics against RSV diseaseSemantic proximity Read ↗

Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.Semantic proximity Read ↗

Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitorSemantic proximity Read ↗

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.Semantic proximity Read ↗

Orally active fusion inhibitor of respiratory syncytial virus.Semantic proximity Read ↗

Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen.Semantic proximity Read ↗

Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.Semantic proximity Read ↗

High-throughput screening of active compounds against human respiratory syncytial virusSemantic proximity Read ↗

RSV604, a novel inhibitor of respiratory syncytial virus replication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.